Medtronic (MDT) Offering Possible 16.28% Return Over the Next 17 Calendar Days

Medtronic's most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $106.00 short put and a strike $101.00 long put offers a potential 16.28% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $106.00 by expiration. The full premium credit of $0.70 would be kept by the premium seller. The risk of $4.30 would be incurred if the stock dropped below the $101.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.

The RSI indicator is at 74.98 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Medtronic

Medtronic EVP & CVG President Mike Coyle to Speak at Wells Fargo Securities Healthcare Conference
Thu, 29 Aug 2019 15:00:00 +0000
Medtronic plc (MDT), the global leader in medical technology, today announced that it will participate in the 14th Annual Wells Fargo Securities Healthcare Conference on Thursday, September 5, 2019, in Boston. Mike Coyle, executive vice president and president of the Cardiac and Vascular Group (CVG) of Medtronic, will answer questions about the company beginning at 8:00 a.m. EDT (7:00a.m. CDT). Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world.

Zacks.com featured highlights include: Target, Medtronic, Microsoft, Teradyne and Darden Restaurants
Thu, 29 Aug 2019 14:32:02 +0000
Zacks.com featured highlights include: Target, Medtronic, Microsoft, Teradyne and Darden Restaurants

Quest Diagnostics' New Acquisitions and Pacts Aid Growth
Thu, 29 Aug 2019 13:56:01 +0000
Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.

5 Top Stocks To Recession-Proof Your Portfolio
Thu, 29 Aug 2019 13:37:55 +0000
No one can predict the future. But nonetheless, the warnings coming from the Street sound particularly ominous right now. “Even as we have been revising our growth projections lower, we continue to highlight that the risks remain decidedly skewed to the downside,” Chetan Ahya, Morgan Stanley’s chief economist, recently cautioned. “We expect that if trade tensions escalate further… we will enter into a global recession (i.e., global growth below 2.5%Y) in three quarters.”That’s why it’s best to get your portfolio in shape before trouble hits. Here are five stocks worth keeping an eye on. All five stocks score a ‘Strong Buy’ consensus from the Street thanks to their compelling outlook. The consensus is based on the last three months of ratings. A couple of these stocks are also top-notch dividend picks. Let’s take a closer look now: 1\. Medtronic PLC (MDT)Ireland based Medtronic is the world's largest medical device company. It has just announced that Geoff Martha will succeed Omar Ishrak as CEO. The news comes after the company reported impressively robust earnings reports. Every reported segment came in above consensus' expectations, with notable strength in Neurovascular, Spine, and Structural Heart.“We don't think that the selection of Martha to succeed Ishrak comes as much of a surprise and we believe that investors think highly of Martha given his track record leading the Spine business and RTG after that” commented Needham’s Mike Matson on August 28.If Martha can further improve upon MDT's execution, Matson believes its multiple could continue to narrow the gap to its large-cap med tech peer group average. Right now, MDT shares trade at a CY20E P/E of 19.4x a roughly 17% discount vs. its large-cap peer group.Net-net: “We reiterate our Strong Buy rating given MDT's improving product cycle and revenue growth and its P/E discount to its large-cap peers”. Out of 17 analysts covering MDT, 14 rate the stock a buy. MDT also pays a 2% dividend yield, with a $2.16 annualized payout; the result of 41 years of consecutive dividend growth. 2\. Clean Harbors Inc (CLH)Clean Harbors is a leading provider of environmental, energy and industrial services. That includes everything from hazardous waste management to industrial cleaning and recycling services. The stock is on a tear so far this year, with shares up 50% year-to-date. And analysts are confident further growth lies ahead.Four out of five analysts covering the stock rate CLH a buy. This includes a recent upgrade from top-rated Oppenheimer analyst Noah Kaye. He bumped the stock from hold to buy with an $88 price target (19% upside potential) following CLH’s beat-and-raise quarter. “We believe Q2 results and commentary provide evidence that Clean Harbors can still generate healthy margin expansion in a low-growth environment, and that consistent execution along with potential catalysts can support another leg up for the shares,” he told investors on August 1. 3\. KB Home (KBH)KB Home- the first company to be traded on the NYSE as a home builder- is enjoying a wave of bullish sentiment from the Street right now. Over the last few months the company has received no less than 6 analyst upgrades. Given that analysts tend to reiterate their ratings, multiple upgrades speak volumes about the stock’s potential. “In the midst of a homebuilding sector where individual stock returns are likely to be highly data-driven, we believe KBH is well positioned with its focus on the entry-level and its strong community count growth” cheers Evercore ISI analyst Stephen Kim. This top-rated analyst upgraded KBH last month, writing “KBH should show some of the highest growth in the space this year, and if the company sustains its order momentum, it has the potential to produce order growth of 30%+ in 4Q.” Meanwhile SunTrust Robinson’s Rohit Seth describes KB Home as “an attractive turnaround story.” 4\. McDonald’s Corp (MCD)Fast food empire McDonald’s has just received its highest price target yet. On August 13 MKM Partners analyst Brett Levy initiated coverage with a buy rating and $250 price target (vs the $230 average analyst price target). McDonald’s “valuations continue to test new highs,” Levy states “but the company has continued to produce strong and consistent results, outpacing much of the other highly franchised global concepts.” Indeed, MCD’s latest earnings report revealed stellar global same-restaurant sales growth of 6.5%, easily beating the 5% consensus estimate. The analyst continued: “We believe the combination of strong domestic and international… sales growth are sustainable through its potential uptick in unit expansion and solid same-store sales generation (through a balanced menu approach and ongoing investments in its stores, systems, technology).”And don’t forget, MCD is also an elite ‘Dividend Aristocrat’. That’s thanks to 42 years of consecutive dividend growth. Investors currently receive an annualized payout of $4.64 on a 2.13% dividend yield. 5\. SilverCrest Metals Inc (SILV)Last but not least we have SilverCrest Metals, an intriguing precious metals exploration company. According to the Street, its flagship Las Chispas project in northwestern Mexico has the potential be one of the highest return projects (+70% IRR at spot prices) in the precious metals space.Indeed, in the last three months, five analysts have published back-to-back buy ratings on SILV. That’s with an average price target of $7.25. And most notably, RBC Capital’s Mark Mihaljevic has just singled out the stock for special praise. He places SILV on RBC Capital’s Q3/2019 list of Canadian Small Cap Conviction Stocks. “We believe SilverCrest’s Las Chispas silver/gold (50%/50%) project has emerged as one of the most promising advanced exploration- stage assets given near-surface high grade mineralization, low capital intensity, and exploration potential” explains Mihaljevic. He believes SilverCrest is a high potential takeover target, as Las Chispas “can add a high-grade, high- margin, high-return project and help fill out the pipeline for many of the [larger] producers.” So watch this space. Discover Wall Street’s best-rated stocks with the Top Analysts’ Stocks tool

Henry Schein Expands SolutionsHub With CueSquared MobilePay
Thu, 29 Aug 2019 11:38:11 +0000
The platform is expected to augment Henry Schein's (HSIC) patient revenues, accelerate payments and curb collection costs.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.